RS67061B1 - Deuterisani derivati ruksolitiniba - Google Patents

Deuterisani derivati ruksolitiniba

Info

Publication number
RS67061B1
RS67061B1 RS20250758A RSP20250758A RS67061B1 RS 67061 B1 RS67061 B1 RS 67061B1 RS 20250758 A RS20250758 A RS 20250758A RS P20250758 A RSP20250758 A RS P20250758A RS 67061 B1 RS67061 B1 RS 67061B1
Authority
RS
Serbia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
myelofibrosis
Prior art date
Application number
RS20250758A
Other languages
English (en)
Serbian (sr)
Inventor
I Robert Silverman
Julie F Liu
Adam J Morgan
Bhaumik Pandya
Scott L Harbeson
Original Assignee
Sun Pharmaceutical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS67061(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries Inc filed Critical Sun Pharmaceutical Industries Inc
Publication of RS67061B1 publication Critical patent/RS67061B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RS20250758A 2012-06-15 2013-06-14 Deuterisani derivati ruksolitiniba RS67061B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US201261678795P 2012-08-02 2012-08-02
EP21156398.6A EP3882249B1 (en) 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib

Publications (1)

Publication Number Publication Date
RS67061B1 true RS67061B1 (sr) 2025-08-29

Family

ID=48699982

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250758A RS67061B1 (sr) 2012-06-15 2013-06-14 Deuterisani derivati ruksolitiniba

Country Status (20)

Country Link
US (7) US20150197525A1 (2)
EP (4) EP2861600A1 (2)
AU (3) AU2013274030B2 (2)
BR (1) BR122023027277A2 (2)
CA (1) CA2876306C (2)
DK (2) DK3450434T3 (2)
EA (1) EA201492287A1 (2)
ES (2) ES2867048T3 (2)
FI (1) FI3882249T3 (2)
HR (1) HRP20250965T1 (2)
HU (1) HUE073180T2 (2)
IN (1) IN2014DN10670A (2)
LT (1) LT3882249T (2)
MX (2) MX373123B (2)
PL (2) PL3882249T3 (2)
PT (1) PT3882249T (2)
RS (1) RS67061B1 (2)
SI (1) SI3882249T1 (2)
SM (1) SMT202500302T1 (2)
WO (1) WO2013188783A1 (2)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
EP3148545B1 (en) 2014-05-28 2023-03-15 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3325479B1 (en) 2015-06-03 2020-12-02 UWM Research Foundation, Inc. Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
AU2017217806A1 (en) * 2016-02-12 2018-08-16 Vertex Pharmaceuticals (Europe) Limited Deuterium-modified CFTR modulators
US10561659B2 (en) * 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3554485B9 (en) 2016-12-14 2023-09-27 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
WO2019104214A1 (en) 2017-11-22 2019-05-31 Dauntless 2, Inc. Membrane emulsification device for microsphere creation
WO2019104225A1 (en) 2017-11-22 2019-05-31 Dauntless 2, Inc. Therapeutic compound formulations
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019171326A1 (en) 2018-03-08 2019-09-12 Novartis Ag Use of an anti-p-selectin antibody
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
KR20260019028A (ko) * 2019-02-06 2026-02-09 썬 파마슈티칼 인더스트리즈 인코포레이티드 거울상 이성질체 풍부한 jak 억제제를 제조하는 방법
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
WO2020210125A1 (en) 2019-04-10 2020-10-15 University Of Notre Dame Du Lac Deuterated antimicrobial compounds
WO2020223640A1 (en) 2019-05-02 2020-11-05 Intel Corporation Quality of service (qos) in information centric networking (icn)
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
CN114450008A (zh) 2019-09-16 2022-05-06 诺华股份有限公司 Mdm2抑制剂用于治疗骨髓纤维化的用途
CN114423786A (zh) 2019-09-16 2022-04-29 诺华股份有限公司 高亲和力的、配体阻断性、人源化的抗T细胞免疫球蛋白结构域和粘蛋白结构域3（TIM-3）IgG4抗体用于治疗骨髓纤维化的用途
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
EP4041204A1 (en) 2019-10-10 2022-08-17 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3194469A1 (en) 2020-08-12 2022-02-17 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
US20240000777A1 (en) 2020-10-08 2024-01-04 Novartis Ag Use of an erk inhibitor for the treatment of myelofibrosis
JP2023553253A (ja) 2020-10-28 2023-12-21 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 重水素化ｊａｋ阻害剤による脱毛障害の治療のためのレジメン
WO2022107131A1 (en) * 2020-11-19 2022-05-27 Sol-Gel Technologies Ltd. Ruxolitinib or deuterated ruxolitinib composition and uses thereof
US12005067B2 (en) 2020-12-04 2024-06-11 Incyte Corporation JAK inhibitor with a vitamin D analog for treatment of skin diseases
EP4274578A1 (en) 2021-01-11 2023-11-15 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
CN114853760B (zh) * 2021-02-03 2025-12-05 南京正大天晴制药有限公司 一种芦可替尼中间体的制备方法
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
EP4384173A1 (en) 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN113820413B (zh) * 2021-09-17 2023-04-07 重庆华邦胜凯制药有限公司 高效液相色谱法分离测定磷酸芦可替尼及杂质的方法
US20250275977A1 (en) 2022-05-04 2025-09-04 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
CN117384163B (zh) * 2022-07-05 2026-02-17 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途
EP4680231A1 (en) * 2023-03-17 2026-01-21 Mayo Foundation for Medical Education and Research Use of oral jak kinase inhibitors to treat lichen planus
CN120917022A (zh) 2023-03-23 2025-11-07 葛兰素史密斯克莱知识产权(第3号)有限公司 氘代p2x3调节剂
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
WO2025226637A1 (en) 2024-04-22 2025-10-30 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
EP2455382B1 (en) * 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
EP3070090B1 (en) * 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
US7855204B2 (en) 2008-01-22 2010-12-21 Concert Pharmaceuticals Inc. Derivatives of gefitinib
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
CN113384546A (zh) * 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型

Also Published As

Publication number Publication date
AU2013274030B2 (en) 2016-07-07
US20190308976A1 (en) 2019-10-10
AU2018271227B2 (en) 2020-08-27
US20150239896A1 (en) 2015-08-27
BR122023027277A2 (pt) 2024-01-23
FI3882249T3 (fi) 2025-08-11
EP3450434A1 (en) 2019-03-06
MX2014015185A (es) 2015-02-17
ES3037872T3 (en) 2025-10-07
CA2876306A1 (en) 2013-12-19
EP3450434B1 (en) 2021-02-24
US9249149B2 (en) 2016-02-02
SI3882249T1 (sl) 2025-10-30
EA201492287A1 (ru) 2015-07-30
WO2013188783A8 (en) 2014-02-27
PL3882249T3 (pl) 2025-09-08
BR112014031204A2 (pt) 2017-06-27
EP4606434A2 (en) 2025-08-27
EP3882249A1 (en) 2021-09-22
WO2013188783A1 (en) 2013-12-19
EP4606434A3 (en) 2025-12-03
IN2014DN10670A (2) 2015-08-28
US20210330674A1 (en) 2021-10-28
US20250025467A1 (en) 2025-01-23
PT3882249T (pt) 2025-08-06
US20230355629A1 (en) 2023-11-09
AU2016238877B2 (en) 2018-08-30
CA2876306C (en) 2024-02-20
EP2861600A1 (en) 2015-04-22
AU2016238877A1 (en) 2016-10-27
MX360495B (es) 2018-11-06
AU2018271227A1 (en) 2018-12-13
SMT202500302T1 (it) 2025-09-12
US20170239254A1 (en) 2017-08-24
ES2867048T3 (es) 2021-10-20
LT3882249T (lt) 2025-08-25
DK3882249T3 (da) 2025-08-25
DK3450434T3 (da) 2021-05-03
PL3450434T3 (pl) 2021-10-04
AU2013274030A1 (en) 2015-01-22
HRP20250965T1 (hr) 2025-10-10
HUE073180T2 (hu) 2026-01-28
MX373123B (es) 2020-04-27
US20150197525A1 (en) 2015-07-16
EP3882249B1 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
US20230355629A1 (en) Deuterated derivatives of ruxolitinib
JP6367545B2 (ja) ルキソリチニブの重水素化誘導体
US20150218158A1 (en) Deuterated baricitinib
EP2943489B1 (en) Deuterated momelotinib
CN104725380B (zh) 卢索替尼的氘代衍生物
KR102433283B1 (ko) 룩소리티닙의 중수소화된 유도체
WO2012129381A1 (en) Deuterated preladenant
HK40060909B (en) Deuterated derivatives of ruxolitinib
HK40060909A (en) Deuterated derivatives of ruxolitinib
JP6830460B2 (ja) ルキソリチニブの重水素化誘導体
HK40013863A (en) Deuterated derivatives of ruxolitinib
HK40013863B (en) Deuterated derivatives of ruxolitinib
BR112014031204B1 (pt) Derivados deuterados de ruxolitinib e composição farmacêutica compreendendo os mesmos
WO2018013686A1 (en) Deuterated idalopirdine